Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
作者信息
Karuturi Meghan, Younes Anas, Fayad Luis, Kwak Larry, Pro Barbara, Shah Jatin, Oki Yasuhiro, Simien Rinata, Liboon Mary Joy, Hutto Toni, Feng Lei, Horowitz Sandra, Nieto Yago, Anderlini Paolo, Alousi Amin, Popat Uday, Medeiros L Jeffrey, Miranda Roberto, Fanale Michelle
机构信息
a Department of Lyphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
b Department of Lymphoma , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
出版信息
Leuk Lymphoma. 2016 Feb;57(2):445-447. doi: 10.3109/10428194.2015.1032966. Epub 2015 Mar 25.
Abstract
摘要
相似文献
1
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
Leuk Lymphoma. 2016 Feb;57(2):445-447. doi: 10.3109/10428194.2015.1032966. Epub 2015 Mar 25.
2
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lancet Haematol. 2021 Aug;8(8):e562-e571. doi: 10.1016/S2352-3026(21)00170-8.
3
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Leuk Lymphoma. 2022 Dec;63(13):3063-3071. doi: 10.1080/10428194.2022.2107204. Epub 2022 Aug 17.
4
High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Bone Marrow Transplant. 1997 Dec;20(11):953-9. doi: 10.1038/sj.bmt.1701002.
5
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Leuk Lymphoma. 2018 Apr;59(4):863-870. doi: 10.1080/10428194.2017.1359741. Epub 2017 Aug 9.
6
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Leuk Lymphoma. 2009 May;50(5):741-8. doi: 10.1080/10428190902853136.
7
High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
J Clin Oncol. 1994 Jun;12(6):1223-31. doi: 10.1200/JCO.1994.12.6.1223.
8
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Medicine (Baltimore). 2020 Dec 4;99(49):e23412. doi: 10.1097/MD.0000000000023412.
9
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
Blood Adv. 2023 Feb 28;7(4):602-610. doi: 10.1182/bloodadvances.2022008802.
10
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Blood Adv. 2018 Dec 26;2(24):3618-3626. doi: 10.1182/bloodadvances.2018022095.
引用本文的文献
1
Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin's lymphoma.
Front Oncol. 2023 Jun 27;13:1153128. doi: 10.3389/fonc.2023.1153128. eCollection 2023.
2
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.
Ther Adv Hematol. 2020 Feb 16;11:2040620720902911. doi: 10.1177/2040620720902911. eCollection 2020.
3
Pharmacotherapeutic Management of Pediatric Lymphoma.
Paediatr Drugs. 2018 Feb;20(1):43-57. doi: 10.1007/s40272-017-0265-x.
4
Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence.
Cell Death Dis. 2016 Nov 10;7(11):e2457. doi: 10.1038/cddis.2016.185.
本文引用的文献
1
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Biol Blood Marrow Transplant. 2015 Nov;21(11):1914-20. doi: 10.1016/j.bbmt.2015.06.003. Epub 2015 Jun 11.
2
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Blood. 2012 Feb 16;119(7):1665-70. doi: 10.1182/blood-2011-10-388058. Epub 2011 Dec 19.
3
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Br J Haematol. 2011 Jul;154(2):284-6. doi: 10.1111/j.1365-2141.2011.08618.x. Epub 2011 Apr 26.
4
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Ann Oncol. 2007 Jun;18(6):1071-9. doi: 10.1093/annonc/mdm090. Epub 2007 Apr 10.
5
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Blood. 2006 Feb 15;107(4):1731-2. doi: 10.1182/blood-2005-09-3731.
6
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Lancet. 2002 Jun 15;359(9323):2065-71. doi: 10.1016/S0140-6736(02)08938-9.
7
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
Blood. 2001 Feb 1;97(3):616-23. doi: 10.1182/blood.v97.3.616.
8
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
J Clin Oncol. 1999 Apr;17(4):1244. doi: 10.1200/JCO.1999.17.4.1244.
9
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Lancet. 1993 Apr 24;341(8852):1051-4. doi: 10.1016/0140-6736(93)92411-l.
10
Adaptive assignment versus balanced randomization in clinical trials: a decision analysis.
Stat Med. 1995 Feb 15;14(3):231-46. doi: 10.1002/sim.4780140302.
Zotero 插件